muraglitazar has been researched along with Hyperplasia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hämäläinen, M; Isotalo, T; Kellomäki, M; Kotsar, A; Laurila, M; Salenius, JP; Suominen, V; Tammela, TL; Uurto, I | 1 |
| Arnold, LL; Cano, M; Cohen, SM; Dominick, MA; Mitroka, J; Sanderson, TP; Schilling, BE; Van Vleet, TR; Waites, CR; White, MR | 1 |
2 other study(ies) available for muraglitazar and Hyperplasia
| Article | Year |
|---|---|
Muraglitazar-eluting bioabsorbable vascular stent inhibits neointimal hyperplasia in porcine iliac arteries.
Topics: Animals; Coated Materials, Biocompatible; Drug-Eluting Stents; Glycine; Hyperplasia; Iliac Artery; Oxazoles; Swine; Tunica Intima | 2015 |
Subchronic urinary bladder effects of muraglitazar in male rats.
Topics: Age Factors; Animals; Apoptosis; Calcium; Cell Proliferation; Citrates; Creatinine; Dose-Response Relationship, Drug; Epidermal Growth Factor; Female; Glycine; Hyperplasia; Magnesium; Male; Oxalates; Oxazoles; Peroxisome Proliferators; Phosphorus; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Sex Factors; Time Factors; Urinary Bladder; Urine; Urothelium | 2007 |